Researchers identified a conspicuous dysregulation of the TGF-β pathway early in the disease process and proposed that the collagen VI–deficient matrix is not capable of regulating the dynamic TGF-β bioavailability both at baseline and in response to muscle injury.
[Journal of Clinical Investigation]